CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer
More about Open Access at the CrickAuthors list
Jesse Boumelha Andrea De Castro Nourdine Bah Hongui Cha Sophie de Carne Sareena Rana Mona Tomaschko Panos Anastasiou Edurne Mugarza Christopher Moore Robert Goldstone Phil East Kevin Litchfield Se-Hoon Lee Miriam Molina Arcas Julian DownwardAbstract
Oncogenic KRAS impairs anti-tumor immune responses. As effective strategies to combine KRAS inhibitors and immunotherapies have so far proven elusive, a better understanding of how oncogenic KRAS drives immune evasion is needed to identify approaches that could sensitize KRAS-mutant lung cancer to immunotherapy. In vivo CRISPR-Cas9 screening in an immunogenic murine lung cancer model identified mechanisms by which oncogenic KRAS promotes immune evasion, most notably via upregulation of immunosuppressive cyclooxygenase-2 (COX-2) in cancer cells. Oncogenic KRAS potently induced COX-2 in both mouse and human lung cancer, which was suppressed using KRAS inhibitors. COX-2 acted via prostaglandin E2 (PGE2) to promote resistance to immune checkpoint blockade (ICB) in lung adenocarcinoma. Targeting COX-2/PGE2 remodeled the tumor microenvironment by inducing pro-inflammatory polarization of myeloid cells and influx of activated cytotoxic CD8+ T cells, which increased the efficacy of ICB. Restoration of COX-2 expression contributed to tumor relapse after prolonged KRAS inhibition. These results provide the rationale for testing COX-2/PGE2 pathway inhibitors in combination with KRASG12C inhibition or ICB in patients with KRAS-mutant lung cancer.
Journal details
Journal
Cancer Research
Volume
84
Issue number
14
Pages
2231-2246
Available online
Publication date
Full text links
Publisher website (DOI)
10.1158/0008-5472.CAN-23-2627
Europe PubMed Central
38635884
Pubmed
38635884
Data and code
Publishing history
The publication was previously a preprint.
View preprint
